ZLc-002

Modify Date: 2023-02-03 18:37:56

ZLc-002 structure	Common Name	ZLc-002
	CAS Number	1446971-41-0	Molecular Weight	231.25
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₀H₁₇NO₅	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of ZLc-002

ZLc-002 is a selective small-molecule inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation[1][2][3].

Name	ZLc-002

Description	ZLc-002 is a selective small-molecule inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation[1][2][3].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Neurological Disease
In Vitro	ZLc-002 (1 μM; 24 h) inhibits nNOS-CAPON in cultured hippocampal neurons from ICR mice[3]. Cell Viability Assay[3] Cell Line: ICR mice hppocampal neurons Concentration: 1 μM Incubation Time: 24 h Result: Inhibited the nNOS-CAPON in cultured hippocampal neurons from ICR mice.
In Vivo	ZLc-002 (30 mg/kg; i.p. from 4-10 days until 46 days after stroke everyday) improves motor function in tMCAO mice[1]. ZLc-002 (40 mg/kg; i.v. once per day for seven days) can improve chronic mild stress (CMS)- induced anxiety-related behaviours[2]. ZLc-002 (10 μM 1 μL; hippocampus injection once per day for seven days) can improve corticosterone (CORT)-induced anxiety-related behaviours[2]. Animal Model: tMCAO mice[2] Dosage: 30 mg/kg Administration: Intraperitoneal injection; 30 mg/kg per day; from 4–10 days until 46 days after stroke Result: Signally ameliorated sroke-induced impairment of motor function and recovered from stroke in the delayed phase. Animal Model: Adult male ICR mice with CMS exposure[2] Dosage: 40 mg/kg Administration: Intravenous injection; 40 mg/kg once per day; from 21-27 days of CMS exposure for 7 days Result: Showed a therapeutic effect in CMS-induced anxiety disorder. Animal Model: Adult male ICR mice with CORT[2] Dosage: 10 μM 1 μL Administration: Hippocampus injection; 10 μM 1 μL once per day; from 21-27 days of CORT reatmentfor 7 days Result: Showed a therapeutic effect in chronic stress-induced anxiety disorders.
References	[1]. Ni HY, et al.Dissociating nNOS (Neuronal NO Synthase)-CAPON (Carboxy-Terminal Postsynaptic Density-95/Discs Large/Zona Occludens-1 Ligand of nNOS) Interaction Promotes Functional Recovery After Stroke via Enhanced Structural Neuroplasticity. Stroke. 2019 Mar;50(3):728-737. [2]. Zhu LJ, et al. nNOS-CAPON blockers produce anxiolytic effects by promoting synaptogenesis in chronic stress-induced animal models of anxiety. Br J Pharmacol. 2020 Aug;177(16):3674-3690. [3]. Zhu LJ, et al.CAPON-nNOS coupling can serve as a target for developing new anxiolytics. Nat Med. 2014 Sep;20(9):1050-4. doi: 10.1038/nm.3644. Epub 2014 Aug 17.

Molecular Formula	C₁₀H₁₇NO₅
Molecular Weight	231.25

ZLc-002

Use of ZLc-002

Names

ZLc-002 Biological Activity

Chemical & Physical Properties